Background: Oral antiplatelet agents have a limitation in their duration of action and bioavailability. Cangrelor is an intravenous adenosine diphosphate (ADP) inhibitor that has a powerful effect, is rapid and reversible within one hour and with the advantage of intravenous administration that reduces variability in the bioavailability of the drug. The study was designed to…
SELECT ACS: The Inclacumab seems to reduce myocardial injury post angioplasty
P-selectin is an adhesion molecule involved in the interactions between endothelial cells, platelets and leukocytes. Inclacumab is a recombinant monoclonal antibody against P-selectin, a potential anti-inflammatory, anti-thrombotic and anti-atherogenic. The objective of the SELECT-ACS was to evaluate whether Inclacumab could reduce myocardial damage during percutaneous coronary intervention (PCI) in patients with non-ST elevation myocardial infarction…
Possible benefit for patients with acute myocardial infarction but without ventricular dysfunction.
Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in patients without heart failure reduces mortality and cardiovascular morbidity. Methods and results: The study randomized 612 patients to evaluate the safety and efficacy of early treatment with eplerenone in patients with AMI. The primary end point was a…
Possible benefit for patients with acute myocardial infarction but without ventricular dysfunction.
Background: To evaluate whether the administration of eplerenone 24 hours after an acute myocardial infarction (AMI) in patients without heart failure reduces mortality and cardiovascular morbidity. Methods and results: The study randomized 612 patients to evaluate the safety and efficacy of early treatment with eplerenone in patients with AMI. The primary end point was a…
PRATO ACS: Rosuvastatin reduces the incidence of contrast nephropathy in patients with acute coronary syndrome who receive early invasive strategy
The aim of this study was to determine whether patients without ST-segment elevation acute coronary syndromes who were not taking statins previously, can receive high doses of rosuvastatin before coronary angiography or angioplasty and if this action could exert protection in renal function and reduce the incidence of contrast-induced nephropathy (CIN). This prospective study randomized…
NEXT trial looked at a non-inferiority degradable polymer stent versus a second-generation permanent polymer stent.
Previous studies of non-inferiority (SORT-OUT III and V) compared the biodegradable polymer biolimus-eluting stent (BES) with permanent polymer stent and sirolimus-eluting stent (SES) or everolimus-eluting stent (EES), showing no differences, although the data is still contradictory. The aim of this study was to evaluate whether the recently approved BES is not inferior to EES in…
PARTNER 2: Edwards SAPIEN XT is even better. Results for PARTNER II, cohort B.
In the PARTNER 1 study, patients with inoperable severe aortic stenosis treated with an aortic valve prosthesis balloon-expandable Edwards-SAPIEN showed a mortality reduction compared with standard treatment. However, the Edwards SAPIEN device is associated with peri-procedural complications. The new generation of Edwards SAPIEN XT prosthesis incorporates significant improvements in the profile of the delivery system,…
DKCRUSH-III: Crushing versus Culotte technique for left main coronary artery
Angioplasty of the unprotected distal left main coronary artery with 2 stents presents the less favorable results in the segment. The double kissing (DK) technique and Culotte technique have been reported as effective for the treatment of bifurcation lesions, however this has never been tested for left main coronary artery. The DKCRUSH-III study investigated the…
STREAM trial: It is time to check out facilitated angioplasty?
It is not clear so far whether pre-hospital fibrinolysis with early angiography could provide a clinical outcome similar to primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). This study included 1,892 patients who presented within three hours of symptom onset and who could not undergo primary angioplasty within the first hour. Patients were…